Cabaletta raises $38M to develop CAR-T-like cell therapies for autoimmune diseases
The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.